Bispecific antibody · Immune activation, directed at CD123 (interleukin-3 receptor alpha chain) (IL3RA) and CD3 complex (CD3E) · developed by MacroGenics
Flotetuzumab is a humanized bispecific antibody built as a DART molecule, binding CD123 on tumor cells and CD3 on T cells. By crosslinking cytotoxic T lymphocytes to CD123-expressing cells, it is designed to drive T-cell-mediated lysis of those cells. It is studied in acute myeloid leukemia, including relapsed disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04582864 | Phase 2 | Relapsed Acute Myeloid Leukemia | Terminated | MGNX |
| NCT02152956 | Phase 1/2 | AML | Terminated | MGNX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AMLRelapsed Acute Myeloid Leukemia
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.
See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGNX catalysts and pipeline →